Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.77 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | HINT1 | P49773 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382556 | 1.00 | TAS1R3 (0.77) | TAS1R3TAS1R1HPGDPAX8IMPDH2 | |
| SCHEMBL413506 | 1.00 | TAS1R3 (0.77) | TAS1R3TAS1R1HPGDPAX8IMPDH2 | |
| SCHEMBL413541 | 0.92 | TAS1R3 (0.66) | TAS1R3TAS1R1HPGDPAX8IMPDH2 | |
| SCHEMBL26246701 | 0.90 | HPGD (0.66) | TAS1R3TAS1R1HPGDPAX8ADORA3 | |
| SCHEMBL31685605 | 0.90 | TAS1R3 (0.66) | TAS1R3TAS1R1HPGDPAX8IMPDH2 | |
| SCHEMBL7156480 | 0.89 | HPGD (0.64) | TAS1R3TAS1R1HPGDPAX8ADORA3 | |
| SCHEMBL15588761 | 0.89 | HPGD (0.64) | TAS1R3TAS1R1HPGDPAX8ADORA3 | |
| SCHEMBL22759956 | 0.89 | HPGD (0.64) | TAS1R3TAS1R1HPGDPAX8ADORA3 | |
| SCHEMBL22434818 | 0.89 | HPGD (0.64) | TAS1R3TAS1R1HPGDPAX8ADORA3 | |
| SCHEMBL19493330 | 0.89 | HPGD (0.64) | TAS1R3TAS1R1HPGDPAX8ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| CN-117886868-A | Preparation method of 5' -DMT nucleoside compound | 天津奥瑞芙生物医药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2023183569-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-9884885-B2 | Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884885-B2 | Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2099316-B1 | FLAVOUR MODULATING DERIVATIVE OF A CARBOXYLIC ACID AND A PURINE, PYRIMIDINE, NUCLEOSIDE OR NUCLEOTIDE | GIVAUDAN SA (CH) | 2017-06-21 | — | — | EP | disclosed |
| CN-103068834-B | Phosphoramidites for reverse RNA synthesis | 坎姆根公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-2415777-B1 | PROCESS FOR PRODUCING NUCLEOSIDE | TAKEDA PHARMACEUTICAL (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8653254-B2 | Process for producing nucleoside | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2415777-A1 | PROCESS FOR PRODUCING NUCLEOSIDE | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2408306-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010134992-A2 | SYNTHESIS LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010134992-A2 | SYNTHESIS LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010108140-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100074850-A1 | Flavour Modulating Derivative of a Carboxylic Acid and a Purine, Pyrimidine, Nucleoside, or Nucleotide | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-03-25 | — | — | US | disclosed |
| EP-2099316-A1 | FLAVOUR MODULATING DERIVATIVE OF A CARBOXYLIC ACID AND A PURINE, PYRIMIDINE, NUCLEOSIDE OR NUCLEOTIDE | Givaudan Nederland Services B.V. (NL) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008072963-A1 | FLAVOUR MODULATING DERIVATIVE OF A CARBOXYLIC ACID AND A PURINE, PYRIMIDINE, NUCLEOSIDE OR NUCLEOTIDE | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074850-A1 | Flavour Modulating Derivative of a Carboxylic Acid and a Purine, Pyrimidine, Nucleoside, or Nucleotide | NUDT1, GART, UMPS | TAS1R3 13/4885TAS1R1 8/4885HPGD 354/4885 |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | TAS1R3 4231/4885TAS1R1 3479/4885HPGD 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.